Literature DB >> 23068583

Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study.

Allan D Sniderman1, Shofique Islam, Salim Yusuf, Matthew J McQueen.   

Abstract

OBJECTIVES: Whether non-HDL-C and apoB are equivalent markers of cardiovascular risk remains controversial. Only when apoB particles in toto contain either more or less cholesterol than normal - that is, when their composition is discordant - could apoB and non-HDL-C predict risk differently. Accordingly, this study tests within the INTERHEART data base whether apoB or non-HDL-C are equivalent markers of risk when the two markers are discordant.
METHODS: The INTERHEART study is a standardized case-control study of acute myocardial infarction with blood samples in 9345 cases and 12,120 controls from 52 countries. To produce comparability, the concentrations of non-HDL-C and apoB are expressed as percentiles (P) within the study population. Concordance is defined as the phenotype when P Non-HDL-C = P apoB (that is, apoB particles contain a normal mass of cholesterol). Discordance is defined either as the phenotype when P Non-HDL-C > P apoB (cholesterol-enriched apoB particles) or P Non-HDL-C < P apoB (cholesterol-depleted apoB particles). The OR of cases to controls was determined for both discordant groups and compared to the ratio of cases to controls in the concordant group, which was the reference group. An OR > 1 means that risk is greater in the discordant than in the reference phenotype whereas an OR < 1 means the cases are less common in the discordant phenotype than in the reference group.
RESULTS: When discordance was defined as percentiles within 5%, a definition that produced equal numbers of discordant and concordant individuals, the OR for P Non-HDL-C > apoB (cholesterol-enriched apoB particles) was 0.72 (0.67-0.77 95% CI) indicating risk was less than the reference concordant group whereas the OR for P Non-HDL-C < apoB (cholesterol-depleted apoB particles) was 1.58 (1.38-1.58 95% CI) indicating risk was significantly greater than the reference concordant group. The same findings were reproduced using all definitions of discordance from 1% to 10%. Moreover, the pattern of findings was consistent amongst the ethnic groups that made up the overall study population.
CONCLUSION: Discordance analysis demonstrates that apoB is a more accurate marker of cardiovascular risk than non-HDL-C.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23068583     DOI: 10.1016/j.atherosclerosis.2012.08.039

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  27 in total

Review 1.  Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.

Authors:  Richard Kones
Journal:  Vasc Health Risk Manag       Date:  2013-10-21

2.  [Clinical value of apolipoprotein B versus low-density lipoprotein cholesterol in assessing risks of coronary artery disease].

Authors:  Si Chen; Jin-Zhen Zhao; Jing Hu; Zhi-Gang Guo
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-07-20

3.  Total cholesterol/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: The ARIC study.

Authors:  Renato Quispe; Mohamed B Elshazly; Di Zhao; Peter P Toth; Rishi Puri; Salim S Virani; Roger S Blumenthal; Seth S Martin; Steven R Jones; Erin D Michos
Journal:  Eur J Prev Cardiol       Date:  2019-07-10       Impact factor: 7.804

4.  Association between discordance of LDL-C and non-HDL-C and clinical outcomes in patients with stent implantation: from the FU-Registry.

Authors:  Michiyo Shiiba; Bo Zhang; Shin-Ichiro Miura; Amane Ike; Daisuke Nose; Takashi Kuwano; Satoshi Imaizumi; Makoto Sugihara; Atushi Iwata; Hiroaki Nishikawa; Akira Kawamura; Kazuyuki Shirai; Shin'ichiro Yasunaga; Keijiro Saku
Journal:  Heart Vessels       Date:  2017-08-16       Impact factor: 2.037

5.  Lipoprotein Biomarkers and Risk of Cardiovascular Disease: A Laboratory Medicine Best Practices (LMBP) Systematic Review.

Authors:  Paramjit K Sandhu; Salma M A Musaad; Alan T Remaley; Stephanie S Buehler; Sonya Strider; James H Derzon; Hubert W Vesper; Anne Ranne; Colleen S Shaw; Robert H Christenson
Journal:  J Appl Lab Med       Date:  2016-08-01

6.  Patient-Level Discordance in Population Percentiles of the Total Cholesterol to High-Density Lipoprotein Cholesterol Ratio in Comparison With Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol: The Very Large Database of Lipids Study (VLDL-2B).

Authors:  Mohamed B Elshazly; Renato Quispe; Erin D Michos; Allan D Sniderman; Peter P Toth; Maciej Banach; Krishnaji R Kulkarni; Josef Coresh; Roger S Blumenthal; Steven R Jones; Seth S Martin
Journal:  Circulation       Date:  2015-07-02       Impact factor: 29.690

7.  Discordance between Circulating Atherogenic Cholesterol Mass and Lipoprotein Particle Concentration in Relation to Future Coronary Events in Women.

Authors:  Patrick R Lawler; Akintunde O Akinkuolie; Paul M Ridker; Allan D Sniderman; Julie E Buring; Robert J Glynn; Daniel I Chasman; Samia Mora
Journal:  Clin Chem       Date:  2017-02-07       Impact factor: 8.327

Review 8.  Apolipoproteins in vascular biology and atherosclerotic disease.

Authors:  Anurag Mehta; Michael D Shapiro
Journal:  Nat Rev Cardiol       Date:  2021-10-08       Impact factor: 32.419

9.  Associations of serum LDL particle concentration with carotid intima-media thickness and coronary artery calcification.

Authors:  Maryam Zaid; Katsuyuki Miura; Akira Fujiyoshi; Robert D Abbott; Takashi Hisamatsu; Aya Kadota; Hisatomi Arima; Sayaka Kadowaki; Sayuki Torii; Naoko Miyagawa; Sentaro Suzuki; Naoyuki Takashima; Takayoshi Ohkubo; Akira Sekikawa; Hiroshi Maegawa; Minoru Horie; Yasuyuki Nakamura; Tomonori Okamura; Hirotsugu Ueshima
Journal:  J Clin Lipidol       Date:  2016-01-06       Impact factor: 4.766

10.  Apolipoprotein B discordance with low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in relation to coronary artery calcification in the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Jing Cao; Sarah O Nomura; Brian T Steffen; Weihua Guan; Alan T Remaley; Amy B Karger; Pamela Ouyang; Erin D Michos; Michael Y Tsai
Journal:  J Clin Lipidol       Date:  2019-11-29       Impact factor: 4.766

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.